Pal-GHK
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
Palmitoyl tripeptide-1 (GHK with a fatty acid tail) is a topical peptide sold for anti-aging skin care, wrinkle reduction, and hydration. The human case is weak: benefits are speculative from small industry-backed trials, and even its better-supported collagen and wound-healing effects (via the parent GHK peptide) are low-confidence. Safety evidence concerns cosmetic use. Cosmetic products are regulated under the FD&C Act without routine FDA premarket approval; no FDA-approved Pal-GHK drug was identified.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Pal-GHK (Palmitoyl Tripeptide-1) is a three-amino-acid peptide attached to a fatty acid chain, designed to penetrate the skin and stimulate collagen production. The core peptide, GHK, was first discovered in human blood plasma in 1973 and is naturally found within type I collagen itself — it acts as a biological signal that tells skin cells to start repairing tissue. The added fatty acid (palmitic acid) helps it absorb through the skin, since the bare peptide is too water-loving to penetrate on its own. Pal-GHK is one of the two active ingredients in the widely used anti-aging complex Matrixyl 3000.
How it works in the body
Palmitoyl Tripeptide-1 — GHK tripeptide attached to a palmitic acid chain for skin penetration. It mimics a collagen breakdown fragment, signaling fibroblasts to produce new collagen, elastin, and glycosaminoglycans. The palmitic acid tail lets it cross the skin barrier and remain active in the dermis.
Research overview
Pal-GHK works by mimicking the natural repair signals your body releases when collagen breaks down. Once absorbed into the skin, it triggers fibroblasts (the cells that build your skin's structural framework) to ramp up production of collagen, elastin, and hyaluronic acid. In Matrixyl 3000, it is formulated with Palmitoyl Tetrapeptide-7, an anti-inflammatory peptide that suppresses IL-6 (a key aging-related inflammatory signal), creating a two-pronged approach to skin renewal. Clinical studies of formulations containing Pal-GHK have shown improvements in wrinkle depth, skin elasticity, firmness, and collagen density. However, a 2025 review noted a 'surprising absence of clinical studies' testing Pal-GHK as the sole active ingredient — most evidence comes from multi-ingredient products. The Cosmetic Ingredient Review Expert Panel concluded in 2018 that it is safe as used in cosmetics at concentrations up to 0.001%. Note: Pal-GHK is different from the copper peptide GHK-Cu, which has a broader research profile beyond skincare.
Who researches Pal-GHK?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching skin health and rejuvenation
Studied for collagen synthesis, skin repair, or anti-aging skin effects.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(5)
Rated by level of concern
Overstated efficacy claims
HighPMID 39963574 (Bioimpacts 2024 — topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective)
Product quality variation (research-grade peptide)
ModeratePMID 19393372 (Anal Chim Acta 2009 — LC-MS/MS method to monitor palmitoyl peptide content in anti-wrinkle cosmetics)
Minimal skin irritation potential
LowPMID 20725584 (32 subjects, 4 weeks); PMID 38932444 (12-week safety assessed by dermatologists and participants)
Lack of reproductive/developmental toxicity data
LowNo reproductive/developmental toxicology studies indexed for palmitoyl tripeptide-1 (absence of evidence, not evidence of safety)
Allergic contact dermatitis (theoretical)
TheoreticalNo indexed case reports identified for GHK or palmitoyl tripeptide-1 contact dermatitis (search-based null finding, not a published safety clearance)
Interaction summary(8)
Rated by direction with this peptide
Microneedling, microneedle patches, and ablative/fractional laser resurfacing
CautionModerateBarrier-breaching procedures bypass the stratum corneum and can deliver a research-grade, non-sterile peptide directly into the dermis, raising the risk of irritation, infection and foreign-body/granulomatous reaction. Peptide microneedle delivery has been studied clinically, but only with pharmaceutically prepared, sterile material — not with gray-market raw peptide.
PMID 31134751 (J Cosmet Dermatol 2020 — 12-week clinical study of bioactive-peptide-loaded hyaluronic acid microneedle patches); PMID 31788907 (2020 — oligoarginine conjugation enhances transdermal delivery of GHK)
Topical retinoids (tretinoin, retinaldehyde, adapalene)
CautionLowReclassified from Synergistic: no co-administration study exists for Pal-GHK, so additive collagen benefit is speculation from shared fibroblast targets. The documented direction of concern is tolerability — retinoid-induced barrier disruption raises peptide penetration and the combined irritation load. Stagger application if the skin is reactive.
Mechanistic only; no co-administration study for Pal-GHK (PMID 39963574 identifies barrier permeability as the limiting factor)
Topical corticosteroids (and intralesional steroids in the same field)
CautionTheoreticalCorticosteroids suppress fibroblast proliferation and procollagen transcription, which would be expected to blunt Pal-GHK's pro-collagen signaling in the same skin area. No study has tested the combination; this is inference from steroid pharmacology, not an observed interaction.
Mechanism-based (known steroid antiproliferative effect on dermal fibroblasts); no published combination data
Alpha- and beta-hydroxy acids (glycolic, lactic, salicylic) and low-pH vitamin C serums
CautionLowAcidic, keratolytic vehicles may destabilize the peptide and strip the barrier, increasing penetration and irritation potential. Layering Pal-GHK immediately after an acid or L-ascorbic acid step is a formulation-stability and tolerability consideration rather than a toxicity one.
Mechanistic/formulation reasoning; peptide instability and permeability discussed in PMID 39963574
Hyaluronic acid
SynergisticLowEvidence is for the copper complex, not Pal-GHK: GHK-Cu combined with low-molecular-weight hyaluronic acid (1:9) raised collagen IV synthesis well above either alone in fibroblast and ex-vivo skin tests. The open-label lip study that reported moisturization gains also paired a palmitoyl tripeptide complex with hyaluronic acid, but among many other actives.
PMID 37062921 (2023 — GHK-Cu and hyaluronic acid synergy on collagen IV, in vitro and ex-vivo); PMID 20725584
Chelating agents in formulation (EDTA, phytic acid) and copper-containing peptide products
CautionTheoreticalPal-GHK is copper-free, and copper-free GHK retains activity in skin models, but much of GHK's described biology is copper-dependent. Chelators in the same vehicle may alter available copper, and using Pal-GHK with a separate GHK-Cu product adds copper exposure without added evidence of benefit.
Mechanistic (copper dependence discussed in PMID 29986520; copper-free GHK activity shown in PMID 23019153)
Tyrosinase-pathway/pigment products (e.g. acetyl tyrosine complexes)
CautionTheoreticalA palmitoyl copper peptide (pal-GHK-Cu) combined with acetyl tyrosine increased tyrosinase activity and melanin production in A375 and B16 melanoma cell lines, so pairing palmitoyl peptides with melanogenesis-promoting actives may work against a hyperpigmentation goal. This is melanoma cell-line data with the copper form, not human skin data with Pal-GHK.
PMID 39632290 (2025 — palmitoyl copper peptide and acetyl tyrosine complex enhances melanin production in A375 and B16 cells)
Systemic medications (oral/injectable drugs generally)
NeutralTheoreticalTopically applied lipidated tripeptides are expected to show negligible systemic absorption and no known cytochrome P450 or transporter activity, so clinically meaningful systemic drug interactions are not anticipated. This reflects absence of evidence rather than formal interaction studies, and would not hold for injected use of research-grade material.
No pharmacokinetic or drug-interaction studies indexed for palmitoyl tripeptide-1
Known risks(5)
Minimal skin irritation potential
Very LowIn CIR-reviewed safety testing, 100 ppm Pal-GHK applied to rabbit skin for 24 hours produced only slight erythema in 2 animals, with no other reactions observed. Human clinical studies of Pal-GHK-containing products have not reported significant irritation or sensitization events. The ingredient is considered suitable for sensitive skin, lip, and eye area applications.
Allergic contact dermatitis (theoretical)
Very LowAs with any peptide or cosmetic ingredient, rare individual allergic reactions are theoretically possible. However, no cases of allergic contact dermatitis from Pal-GHK have been reported in the published literature or CIR safety assessment. Patch testing data shows no sensitization.
Lack of reproductive/developmental toxicity data
The CIR 2018 safety assessment noted that data on the reproductive and developmental toxicity of Palmitoyl Tripeptide-1 were not available. The Panel considered this acceptable given the very low use concentrations (<10 ppm) and topical-only application route, but this remains a data gap.
Product quality variation (research-grade peptide)
Low-ModerateUnregulated Pal-GHK products sold online vary in purity (95-99%) and may contain synthesis byproducts. Using raw peptide powder to formulate homemade skincare without proper formulation expertise could result in irritation or instability. Commercial skincare products from established brands undergo proper formulation and quality control.
Overstated efficacy claims
Low (financial risk, not safety risk)A 2025 review (PMID 39963574) noted a 'surprising absence of clinical studies' for Pal-GHK despite widespread commercial marketing claims. Consumers may pay premium prices for products whose anti-aging efficacy has not been rigorously demonstrated in large, independent, placebo-controlled trials.
Drug interactions(5)
Topical retinoids (tretinoin, adapalene, tazarotene, retinol)
No known adverse interaction. Pal-GHK and retinoids both stimulate collagen synthesis but through different mechanisms (matrikine signaling vs. RAR/RXR nuclear receptor activation). Pal-GHK may help offset retinoid-induced irritation due to its non-irritating profile. No contraindication.
Topical acids (AHAs, BHAs, vitamin C / L-ascorbic acid)
No documented adverse interaction. However, peptides including Pal-GHK can be degraded by extreme pH conditions. Highly acidic formulations (pH <3.5, as with some L-ascorbic acid serums) may hydrolyze the peptide bond and reduce efficacy. Some skincare experts recommend applying acid-based products and peptide products at separate times (e.g., morning/evening) rather than layering simultaneously.
Topical niacinamide
No adverse interaction. Niacinamide and Pal-GHK are often formulated together in anti-aging products. Both support barrier function and collagen synthesis through complementary mechanisms.
Copper-containing products (GHK-Cu, copper-infused skincare)
No documented adverse interaction, but redundancy is possible since both Pal-GHK and GHK-Cu derive from the same parent tripeptide and stimulate similar pathways. Using both simultaneously is unlikely to cause harm but may not provide additive benefit.
Systemic medications (oral drugs)
No known systemic drug interactions. Pal-GHK is applied topically at extremely low concentrations (1-10 ppm) and has negligible systemic absorption. It is not expected to interact with any oral medications, including immunosuppressants, chemotherapy agents, or metabolic drugs.
Research & benefits
Evidence base
- Evidence Level
- Moderate
- Total Studies
- 12
- Human Studies
- 6
Clinical evidence for Pal-GHK is modest but consistent. The peptide's efficacy data comes primarily from manufacturer-sponsored studies (Sederma/Croda for Biopeptide CL and Matrixyl 3000) and small open-label cosmetic trials. These typically involve 15-35 female subjects, durations of 4-12 weeks, and assessment by objective dermatological measurements (corneometry, cutometry, profilometry, ultrasound collagen density). Results consistently show statistically significant improvements in wrinkle parameters, skin elasticity, hydration, and collagen density. However, the active formulations almost always contain Pal-GHK in combination with other actives (Pal-Tetrapeptide-7, growth factors, hyaluronic acid), making it difficult to attribute effects to Pal-GHK alone. In vitro evidence for collagen stimulation by GHK/GHK-Cu is strong and well-replicated across multiple labs since 1988. The CIR Expert Panel's 2018 safety review confirmed the ingredient is safe as used in cosmetics. A 2025 review (PMID 39963574) explicitly noted the 'surprising absence' of rigorous clinical studies isolating Pal-GHK's contribution.
Researched for(7)
Rated by confidence in the evidence
Stimulation of collagen synthesis in dermal fibroblasts
LowShown in cultured fibroblasts specifically for Pal-GHK; not confirmed in living skin or human trials.
PMID 41527525 (Wang et al., J Cosmet Dermatol 2026) is direct cell-culture evidence for Pal-GHK (PT-1) itself, showing it boosts nighttime fibroblast collagen synthesis. PMID 18644225 (Pickart 2008) and PMID 26236730 (Pickart 2015) are reviews of the related but distinct parent compound GHK/GHK-Cu describing the same general collagen-stimulation mechanism; they support plausibility but do not test Pal-GHK directly, so citing them as primary evidence for this specific peptide overstates their relevance.
Reduction of facial wrinkles (depth, length, and volume)
SpeculativePublished evidence mostly concerns combinations; CIR also summarizes a blinded Pal-GHK-versus-vehicle study involving 15 women.
PMID 39963574 (Bioimpacts 2024 review — notes absence of clinical studies). PMID 38932444 (Skin Res Technol 2024 — multi-component eye cream, 12 weeks). PMID 41527525 (J Cosmet Dermatol 2026 — 30-subject day/night regimen trial).
Improved skin hydration, elasticity, and collagen density
SpeculativeMeasured in a 12-week multi-ingredient trial; effect not isolated to Pal-GHK alone.
PMID 38932444 (Skin Res Technol 2024 — 12-week instrumental and ultrasound outcomes, multi-component); PMID 39963574
Enhanced lip moisturization and fullness
SpeculativeBased on one small open-label lip study with no control group or isolated arm.
PMID 20725584 (J Clin Aesthet Dermatol 2009 — open-label combination lip treatment, n=32)
Stem cell recovery and keratinocyte proliferation (GHK parent peptide)
SpeculativeShown only in cell-culture models of the parent peptide GHK, not Pal-GHK itself.
PMID 23019153 (J Pept Sci 2012 — stem cell recovering effect of copper-free GHK in skin)
Wound healing acceleration (GHK parent peptide)
LowAccelerated healing in diabetic rat studies of GHK-Cu; human GHK-Cu ulcer trials exist, but no Pal-GHK wound trial was identified.
PMID 17049946 (Biomaterials 2007 — biotinylated GHK collagen matrices, diabetic rat model); PMID 18644225 (review); PMID 29986520 (Int J Mol Sci 2018 — review of GHK-Cu regenerative actions)
Modulation of multiple cellular pathways in skin regeneration
LowGene-expression studies show broad repair-pathway activity for GHK, not a clinical outcome.
PMID 26236730 (Biomed Res Int 2015); PMID 29986520 (Int J Mol Sci 2018)
Benefits(7)
Stimulation of collagen synthesis in dermal fibroblasts
Maquart et al. 1988 (FEBS Letters, PMID 3169264) — Seminal study showing GHK-Cu stimulates collagen synthesis in fibroblast cultures. Stimulation began between 10^-12 and 10^-11 M, maximized at 10^-9 M, independent of cell number changes. Matrixyl 3000 in vitro studies (Sederma/Croda) demonstrated dose-dependent upregulation of type I and type IV collagen production by palmitoyl tripeptide-1 in human dermal fibroblasts.
Reduction of facial wrinkles (depth, length, and volume)
Matrixyl 3000 clinical studies (Sederma) — In a study of female participants, 2 months of treatment with Matrixyl 3000 (containing Pal-GHK + Pal-Tetrapeptide-7) reduced the area occupied by deep wrinkles by 45% and increased skin tonicity by nearly 20%. Sederma Biopeptide CL study — A cream containing palmitoyl tripeptide-1 at 3 ppm applied twice daily for 4 weeks to 15 female subjects showed statistically significant reductions in wrinkle length and depth, and skin roughness.
Improved skin hydration, elasticity, and collagen density
Yang et al. 2024 (Skin Research and Technology, PMID 38932444) — A 12-week clinical trial of an eye cream containing palmityl tripeptide-1 and palmitoyl tetrapeptide-7 among other actives showed substantial improvements in skin hydration (28.12%), elasticity (18.81%), and collagen production (54.99%) measured by ultrasound.
Enhanced lip moisturization and fullness
Clinical assessment of lip treatment (PMID 20725584) — A 4-week open-label study of 32 women ages 22-40 using a lip formulation containing palmitoyl-glycyl-histidyl-lysine complex showed statistically significant improvements (P<0.001) in lip scaling, texture, dryness, perioral wrinkles, and lip fullness at both 2 and 4 weeks.
Stem cell recovery and keratinocyte proliferation (GHK parent peptide)
Choi et al. 2012 (J Peptide Science, PMID 23019153) — Copper-free GHK increased keratinocyte proliferation, enhanced basal cell morphology in skin equivalent models, and upregulated p63 and PCNA-positive basal cells, indicating stem cell recovering effects in skin.
Wound healing acceleration (GHK parent peptide)
Arul et al. 2005 (J Biomed Mater Res B, PMID 15803494) — Biotinylated GHK incorporated into collagen matrix showed enhanced wound contraction, increased cell proliferation, and high expression of antioxidant enzymes in rat dermal wound healing model. Pickart 2008 (J Biomater Sci Polym Ed, PMID 18644225) — Review of GHK's role in tissue remodeling, wound healing of skin, hair follicles, GI tract, bone, and dog foot pads.
Modulation of multiple cellular pathways in skin regeneration
Pickart et al. 2015 (BioMed Res Int, PMID 26236730) — Comprehensive review demonstrating GHK stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate, and decorin; modulates MMPs and TIMPs; attracts immune and endothelial cells; and restores replicative vitality to fibroblasts after radiation therapy.
Key studies(5)
Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+
In vitro (cell culture)Fibroblast culturesAcute exposure experimentsMaquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP
FEBS Letters
1988
Seminal study establishing GHK-Cu stimulates collagen synthesis in fibroblasts. Stimulation began between 10^-12 and 10^-11 M, maximized at 10^-9 M, and was independent of cell number changes. Identified the GHK triplet in the alpha-2(I) chain of type I collagen, suggesting it may be liberated by proteases during wound healing.
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
ReviewN/A (comprehensive review)Pickart L, Vasquez-Soltero JM, Margolina A
BioMed Research International
2015
Comprehensive review of GHK biology. Demonstrated GHK stimulates collagen, dermatan sulfate, chondroitin sulfate, and decorin synthesis. Modulates MMPs/TIMPs, attracts immune and endothelial cells, accelerates wound healing across multiple tissue types, and restores replicative vitality to irradiated fibroblasts. In cosmetics, it tightens skin, reduces wrinkles, and improves elasticity.
Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective
ReviewN/A (comprehensive review)Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR
BioImpacts
2025
Most up-to-date review of GHK and its derivatives (GHK-Cu, Pal-GHK) as anti-wrinkle agents. Confirmed cellular evidence supports GHK as effective anti-wrinkle ingredient. Noted 'surprising absence of clinical studies' for GHK-Cu and Pal-GHK despite widespread commercial use. Reviewed skin permeation challenges and enhancement strategies including microneedles, cell-penetrating peptides, and metal complexation.
Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream
Clinical trial (open-label, 12-week)Human subjects (periorbital application)12 weeks with assessments at 4, 8, and 12 weeksYang F, Zhang X, Wang H, et al.
Skin Research and Technology
2024
Eye cream containing palmityl tripeptide-1, palmitoyl tetrapeptide-7, and other actives demonstrated substantial improvements: skin hydration +28.12%, elasticity +18.81%, collagen production +54.99% (measured by ultrasound) after 12 weeks. Significant improvements in moisture, roughness, elasticity, fine lines, and wrinkles observed by week 8. High safety profile confirmed.
Stem cell recovering effect of copper-free GHK in skin
In vitro (cell culture and skin equivalent models)Human keratinocytes and skin equivalent modelsCulture periodChoi HR, Kang YA, Ryoo SJ, Shin JW, Na JI, Huh CH, Park KC
Journal of Peptide Science
2012
Copper-free GHK (the parent peptide of Pal-GHK) increased keratinocyte proliferation, improved basal cell morphology to more cuboidal shape in skin equivalents, enhanced alpha-6 and beta-1 integrin staining along basement membrane, and increased p63 and PCNA-positive basal cells — indicating stem cell recovering effects in skin.
Regulation & availability
Why researchers look at it
A key ingredient in the widely used Matrixyl 3000 complex, with clinical studies showing improvements in wrinkle depth, elasticity, and collagen density — yet clinical evidence remains limited; CIR describes a small controlled study of Pal-GHK. If future research isolates its individual contribution, it could move from promising cosmetic ingredient to validated standalone anti-aging peptide.
- Estimated cost
- $15-50/mo in OTC serums (often as Matrixyl 3000 component)
- FDA status
- Pal-GHK is a cosmetic ingredient, not an FDA-approved drug. It is regulated as a cosmetic ingredient under the Federal Food, Drug, and Cosmetic Act; FDA does not approve cosmetic ingredients before sale, and a product that claims to treat a condition or change how the body works is regulated as a drug. Historical VCRP data documented Pal-GHK use in cosmetics. FDA stopped accepting VCRP submissions on March 27, 2023. MoCRA now requires safety substantiation, serious-adverse-event reporting and, where applicable, facility registration and product listing.
- WADA status
- Pal-GHK is not named in the 2026 WADA Prohibited List. That does not establish compound-specific clearance: S0 covers qualifying unapproved pharmacological substances, and S2 is not generally restricted to injectable products. Topical cosmetic use alone does not establish an exemption. No Pal-GHK-specific determination or evidence supporting zero systemic exposure, undetectability or zero anti-doping risk was verified.
- Prescribability
- Pal-GHK (Palmitoyl Tripeptide-1) is NOT a prescription drug and is not prescribable by physicians. It is classified as a cosmetic ingredient, not a pharmaceutical. It has never been submitted for FDA drug approval and has no Investigational New Drug (IND) status. People access Pal-GHK exclusively through over-the-counter cosmetic and skincare products.
- Availability
- Pal-GHK (Palmitoyl Tripeptide-1) is widely available without prescription in commercial skincare products. It is a common ingredient in premium anti-aging serums, creams, and eye treatments. The most recognized commercial form is Matrixyl 3000 (Sederma/Croda), which pairs Pal-GHK with Palmitoyl Tetrapeptide-7 and is licensed to hundreds of skincare brands. Products from The Ordinary, Paula's Choice, SkinCeuticals, Peter Thomas Roth, and many others contain palmitoyl tripeptide-1. Typical retail prices range from $10-80 for consumer serums. No prescription, compounding pharmacy, or medical access pathway exists or is needed: this is a cosmetic ingredient, not a drug.
International status
EU
Available OTC in cosmetics (INCI listed)
US
Available OTC in cosmetic products (not a drug)
Worldwide
Regulated as cosmetic ingredient, not pharmaceutical
Regulatory timeline(10)
- 1973-05Loren Pickart and Melvin Thaler discover GHK in human serum. Published in Nature New Biology (PMID 4349963) — a small peptide fraction from young human plasma caused old liver tissue to synthesize proteins like younger tissue.
- 1977The growth-modulating peptide is identified as the tripeptide glycyl-L-histidyl-L-lysine (GHK). Its copper-binding properties are characterized.
- 1988-10Maquart, Pickart et al. publish seminal study in FEBS Letters (PMID 3169264) demonstrating GHK-Cu stimulates collagen synthesis in fibroblast cultures at picomolar concentrations. Identify the GHK sequence within alpha-2(I) collagen chain.
- 1990sGHK-Cu enters commercial skincare and wound healing markets. Cosmetic applications for anti-aging begin to emerge. Sederma (now part of Croda International) develops palmitoylated derivative (Pal-GHK) to improve skin penetration.
- 2000s-earlySederma launches Biopeptide CL (trade name for Palmitoyl Tripeptide-1) as a cosmetic active ingredient. Initial manufacturer-sponsored clinical studies on wrinkle reduction. Also launches Matrixyl 3000 combining Pal-GHK with Palmitoyl Tetrapeptide-7.
- 2012-07CIR Expert Panel publishes Safety Assessment of Palmitoyl Oligopeptides as Used in Cosmetics, an initial review covering palmitoyl peptides in cosmetic use.
- 2015Pickart et al. publish comprehensive review 'GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration' in BioMed Research International (PMID 26236730), establishing GHK's broad biological significance.
- 2018CIR Expert Panel publishes final Safety Assessment of Tripeptide-1, Hexapeptide-12, their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 (Int J Toxicol, DOI: 10.1177/1091581818807863). Concludes Palmitoyl Tripeptide-1 is safe as used in cosmetics at current concentrations (typically <10 ppm).
- 2022-12Modernization of Cosmetics Regulation Act (MoCRA) signed into law, enhancing FDA oversight of cosmetic ingredients. Pal-GHK-containing products will be subject to new requirements including mandatory adverse event reporting and facility registration.
- 2025Mortazavi et al. publish review (BioImpacts, PMID 39963574) noting widespread commercial use of Pal-GHK but 'surprising absence of clinical studies.' Highlight ongoing challenges in skin permeation and formulation stability.
Sources & FAQs
Research sources(15)
- Pickart L, Thaler MM 1973 — Original GHK discovery from human plasma
- Maquart et al. 1988 — GHK-Cu stimulation of collagen synthesis in fibroblasts
- Arul et al. 2005 — Biotinylated GHK collagen matrix for dermal wound healing
- Pickart L 2008 — The human tri-peptide GHK and tissue remodeling (review)
- Clinical assessment of lip treatment containing Pal-GHK 2009
- Pickart et al. 2012 — GHK-Cu in prevention of oxidative stress and aging
- Choi et al. 2012 — Stem cell recovering effect of copper-free GHK in skin
- Pickart et al. 2015 — GHK as natural modulator of cellular pathways in skin regeneration
- Pickart et al. 2017 — GHK and gene expression in nervous system function
- Johnson et al. 2018 — CIR Safety Assessment of Tripeptide-1 and derivatives
- Yang et al. 2024 — Efficacy of anti-aging eye cream with palmityl tripeptide-1
- Mortazavi et al. 2025 — GHK as anti-wrinkle peptide: advantages, problems, prospective
- Development of LC-MS/MS method for palmitoyl peptides in cosmetics
- CIR Safety Assessment of Palmitoyl Oligopeptides (2012 report)
- Wang et al. 2026 — Targeting circadian rhythm for skin collagen metabolism
Frequently asked questions(5)
What is the difference between Pal-GHK and GHK-Cu (copper peptide)?
Both derive from the same parent tripeptide GHK (Gly-His-Lys), but they are modified differently. Pal-GHK has a palmitic acid (C16 fatty acid) chain attached to increase lipophilicity and skin penetration for topical cosmetic use. GHK-Cu is a complex of GHK with a copper(II) ion, which has a broader biological research profile including wound healing, anti-inflammatory effects, and gene expression modulation. Pal-GHK is used exclusively in skincare products, while GHK-Cu has applications in both cosmetics and wound care research.
Is Pal-GHK the same as Matrixyl 3000?
No. Matrixyl 3000 is a trade name (by Sederma/Croda) for a specific combination of TWO peptides: Palmitoyl Tripeptide-1 (Pal-GHK) and Palmitoyl Tetrapeptide-7. The two peptides are designed to work synergistically — Pal-GHK stimulates collagen and ECM synthesis, while Palmitoyl Tetrapeptide-7 reduces inflammation by suppressing IL-6. Many anti-aging products advertise 'Matrixyl 3000' on their labels. Pal-GHK is one of the two active components.
What concentration of Pal-GHK is effective in skincare products?
Clinical studies have used Pal-GHK at 3-4 ppm (parts per million), which corresponds to 0.0003-0.0004% by weight. The CIR safety assessment covers use up to 10 ppm (0.001%). The peptide is active at very low concentrations — the original GHK-Cu collagen stimulation studies showed effects beginning at picomolar (10^-12 M) concentrations.
Can Pal-GHK replace retinol for anti-aging?
Manufacturer data (Sederma) claims Pal-GHK is 'comparable to retinoic acid' in collagen stimulation activity without triggering irritation. However, this comparison comes from limited in vitro data, not head-to-head clinical trials. Retinoids (tretinoin, retinol) have decades of rigorous clinical evidence in large RCTs demonstrating efficacy for photoaging, wrinkles, and hyperpigmentation. Pal-GHK has much weaker clinical evidence. Many dermatologists recommend peptides as complementary to, rather than a replacement for, retinoids — especially for those with sensitive skin who cannot tolerate retinoids.
Is Pal-GHK safe for sensitive skin and around the eyes?
Yes. The CIR Expert Panel's 2018 safety assessment confirmed safety in cosmetic use. In skin irritation testing, 100 ppm Pal-GHK showed only slight erythema in 2 of multiple rabbits tested, and genotoxicity assays were negative. Clinical studies specifically testing eye creams containing Pal-GHK (PMID 38932444) reported high safety profiles. Unlike retinoids, AHAs, or vitamin C at high concentrations, Pal-GHK is generally non-irritating and well-suited for the delicate periorbital area.